Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MLYCD | O95822 | 2/20 | 0.47 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.43 |
| ▸ | CDK4 | P11802 | 7/20 | 0.42 |
| ▸ | CCND1 | P24385 | 7/20 | 0.42 |
| ▸ | CDK2 | P24941 | 3/20 | 0.42 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.39 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.39 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.39 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.39 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | ESRRG | P62508 | 1/20 | 0.37 |
| ▸ | MMP2 | P08253 | 1/20 | 0.37 |
| ▸ | MMP9 | P14780 | 1/20 | 0.37 |
| ▸ | MMP8 | P22894 | 1/20 | 0.37 |
| ▸ | TACR1 | P25103 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Benzylamine SCHEMBL6793711 | 0.79 | MMP2 (0.39) | MMP2MMP9MMP8 | |
| SCHEMBL6789361 | 0.79 | MMP2 (0.41) | MMP2MMP9MMP8 | |
| SCHEMBL6791153 | 0.79 | MMP2 (0.41) | MMP2MMP9MMP8 | |
| SCHEMBL6791227 | 0.79 | MMP2 (0.41) | MMP2MMP9MMP8 | |
| SCHEMBL6944232 | 0.78 | ROCK2 (0.49) | ROCK2ROCK1HDAC6 | |
| SCHEMBL6793526 | 0.78 | CA12 (0.40) | MMP2MMP9MMP8 | |
| SCHEMBL6793713 | 0.76 | MMP2 (0.37) | ROCK2ROCK1MMP2MMP9MMP8 | |
| SCHEMBL6793269 | 0.72 | MEN1 (0.36) | MMP2MMP9MMP8 | |
| SCHEMBL12133560 | 0.71 | MLYCD (0.72) | MLYCDMCHR1CDK4CCND1HDAC6 | |
| SCHEMBL6793095 | 0.71 | DHODH (0.47) | MMP2MMP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040147573-A1 | Metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2004-07-29 | — | — | US | disclosed |
| US-20040110809-A1 | Metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2004-06-10 | — | — | US | disclosed |
| EP-1370538-A1 | METALLOPROTEINASE INHIBITORS | AstraZeneca AB (SE) | 2003-12-17 | — | — | EP | disclosed |
| WO-2002074752-A1 | METALLOPROTEINASE INHIBITORS | ASTRAZENECA AB (SE) | 2002-09-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110809-A1 | Metalloproteinase inhibitors | MMP9, MMP2, MMP3 | MLYCD 2239/4885MCHR1 3380/4885CDK4 927/4885 |
| US-20040147573-A1 | Metalloproteinase inhibitors | MMP12, MMP7, MMP10 | MLYCD 2963/4885MCHR1 2038/4885CDK4 4094/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.